PR90170

ST. CHARLES, Mo., June 22, 2021 /PRNewswire=KYODO JBN/ --

Eurofins Discovery, the leading provider of products and services to the drug

discovery industry and a Eurofins Scientific (EUFI.PA) company, and

ImmunoPrecise Antibodies (Nasdaq:IPA), the market leader in full-service

therapeutic discovery and development, announced a commercial collaboration.

Leveraging complementary strengths in Eurofins Discovery's in vitro

pharmacology services and ImmunoPrecise's in vivo characterization and

discovery technologies, this collaboration provides greater access to solutions

that empower scientists to pursue life-changing medicines in a diverse range of

indications.

Logo - https://mma.prnewswire.com/media/848249/DISCOVERY_Logo.jpg

Logo - https://mma.prnewswire.com/media/1536017/ImmunoPrecise_Logo.jpg

Eurofins Discovery's global clients will have access to ImmunoPrecise's

end-to-end antibody discovery capabilities using wild type and best-in-class in

vivo antibody discovery technologies that are optimized to deeply mine antibody

repertoires. This collaboration supports Eurofins Discovery's biotherapeutics

strategy to extend their capacity and capability to develop new biologic

entities, guiding clients from target validation through preclinical

development, production, and beyond with the expertise required to address the

unique challenges of each discovery project.

As the leading global innovation-driven and customer-focused providers,

Eurofins Discovery and ImmunoPrecise share common values in the culture of

collaboration and the unrelenting pursuit of service excellence.

For further information

www.eurofinsdiscoveryservices.com

About Eurofins Discovery

Eurofins Discovery has supported Drug Discovery research for over 40 years.

Eurofins is recognized as the industry leader for providing drug discovery

researchers the largest and most diverse portfolio of standard and custom in

vitro safety & pharmacology assays and panels for drug screening and profiling.

In addition to in vitro safety pharmacology strengths, we also offer a broad

portfolio of over 3500 drug discovery services and 1800 products. These include

in vitro assays, cell-based phenotypic assays, safety pharmacology and

efficacy, ADME toxicology, medicinal chemistry design, synthetic chemistry, and

custom proteins and assay development capabilities. We support a variety of

drug discovery targets such as GPCRs, Kinases, Ion Channels, Nuclear Hormone

Receptors and other proteins & enzymes. The Eurofins Discovery capabilities,

expertise, knowledge and skill sets enable the company to provide clients the

benefit of being able to work with a single outsourcing provider (CRO) for all

their drug discovery programs.

About Eurofins -- the global leader in bio-analysis

Eurofins is Testing for Life. Eurofins is the global leader in food,

environment, and pharmaceutical product testing. It is also one of the market

leaders in testing and laboratory services for genomics, discovery

pharmacology, forensics, advanced material sciences and has a rapidly

developing presence in highly specialised and molecular clinical diagnostic

testing.

With over 50,000 staff across a network of more than 800 laboratories in over

50 countries, Eurofins' companies offer a portfolio of over 200,000 analytical

methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.

About ImmunoPrecise Antibodies

ImmunoPrecise is an innovation-driven technology platform company that supports

its business partners in their quest to discover and develop novel antibodies

against all classes of disease targets. The company aims to transform the

conventional multi-vendor antibody discovery model by providing a comprehensive

suite of services tailored to optimize antibody genetic diversity and epitope

coverage, to discover antibodies against rare and/or challenging epitopes. For

further information, visit www.immunoprecise.com or contact

solutions@immunoprecise.com.

SOURCE Eurofins Discovery

CONTACT: Media Contact: Aida Yodites, Director Marketing Communications,

AidaYodites@eurofinsus.com; Investors Contact: LifeSci Advisors, John Mullaly,

jmullaly@lifesciadvisors.com